OGT to exhibit and present at Molecular Medicine Tri-Con 2012
Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, will be exhibiting and presenting its biomarker discovery service at the Molecular Medicine Tri-Con in San Francisco, California (19th-23rd February 2012). The conference, organized by the Cambridge Healthtech Institute, will include an OGT presentation entitled “Integrated Biomarker Discovery: Multi-Method Approach to Enable Early Biomarker Success”, taking place on Tuesday 21st February at 15.50 in the Moscone North Convention Centre. The talk, given by Dr Graham Speight, Head of Genomic Biomarkers at OGT, will explain how high-throughput biomarker discovery can generate rich datasets identifying a number of biologically relevant disease markers, making it useful for validation, proof of concept and in depth analysis.
Will Colón, OGT’s Business Development Director, Biomarker Discovery, commented: “OGT’s expertise in genomic- and protein- based arrays makes us ideally placed to offer a powerful, integrated range of biomarker discovery solutions. As well as DNA arrays, we have developed a unique “functional protein” array technology, which conserves the in vivo conformation of each protein when attached to the surface of the array. This enables the discovery of autoantibody biomarkers with maximum sensitivity and specificity. Utilising our high-throughput workflow procedures, and over 140 quality control steps, our biomarker discovery service uses only the minimum amount of precious clinical sample necessary to produce insightful results.”
As well as exhibiting and presenting at the conference, OGT will also provide details of its Genefficiency™ genomic products and services as part of the Molecular Medicine Tri-Con product showcase. This will include OGT’s Targeted Sequencing Service, which is designed to provide meaningful results rather than insurmountable data sets, achieved via OGT’s internationally recognised probe design, data analysis expertise and independently- accredited quality control procedures. This service has recently been extended to cover the genomic analysis of rare diseases, providing an option specifically optimised to help investigators and clinicians identify causative mutations quickly, easily and without the need for in-house practical or bioinformatics expertise.
To find out more about the full range of products and services offered by OGT, visit www.ogt.co.uk.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: firstname.lastname@example.org
Notes for editors:
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine. The company has two trading businesses: Genomics comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomic Services, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.
CytoSure™ and Genefficiency™ NGS browser: For Research Use Only; Not for Use in Diagnostic Procedures
CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.